Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619678 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT06619678 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 36 participants.
The verdict
NCT06619678, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507. Researchers will also compare MK-8507 given alone to MK-8507 given with Islatravir.
Interventions
- DRUG Islatravir
- DRUG MK-8507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-01-17 |
| Est. Completion | 2024-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06619678
The ClinicalTrials.gov registry entry for NCT06619678 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Islatravir is the first listed.
NCT06619678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06619678 about?
NCT06619678 is a clinical study titled "A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)". The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507. Researchers will also compare MK-8507 given alone to MK-8507 given with Islatravir.
What is the current status of trial NCT06619678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-01-17. Estimated completion is 2024-06-23.
What interventions are being tested in trial NCT06619678?
The interventions under investigation include: Islatravir (DRUG), MK-8507 (DRUG).
Who is sponsoring clinical trial NCT06619678?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.